Post hoc analysis: Reduction in risk of clinical fractures after a single dose of zoledronic acid

Source: Journal of Clinical Endocrinology and Metabolism Area: News Annual infusions of zoledronic acid 5 mg over 3 years have been shown to produce stable reductions in biochemical markers of bone turnover, have sustained increases in bone mineral density (BMD), and reduce the incidence of vertebral, hip, and nonvertebral fractures compared with placebo in women with postmenopausal osteoporosis. More recently, data regarding the duration of effect of single doses of zoledronic acid on BMD and markers of bone turnover have raised the question of whether zoledronic acid administration at intervals of longer than 1 year results in a reduced risk of fractures.   To address this issue, researchers used data from the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT) and Recurrent Fracture Trial (HORIZON-RFT) databases to determine whether fracture risk is decreased in participants who received a single infusion of zoledronic acid in comparison with those who received a single infusion of ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news